TD Cowen Forecasts Strong Price Appreciation for Thermo Fisher Scientific (NYSE:TMO) Stock

Thermo Fisher Scientific (NYSE:TMO) had its target price lifted by stock analysts at TD Cowen from $612.00 to $654.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has a “buy” rating on the medical research company’s stock. TD Cowen’s target price would suggest a potential upside of 14.12% from the company’s previous close.

TMO has been the subject of a number of other research reports. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Thermo Fisher Scientific in a report on Thursday. JPMorgan Chase & Co. boosted their price target on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a report on Thursday, October 9th. Evercore ISI boosted their price target on shares of Thermo Fisher Scientific from $525.00 to $590.00 and gave the company an “outperform” rating in a report on Tuesday, October 7th. Redburn Partners set a $580.00 price target on shares of Thermo Fisher Scientific in a report on Wednesday, October 8th. Finally, HSBC restated a “hold” rating and issued a $510.00 price target on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Nineteen research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, Thermo Fisher Scientific has an average rating of “Moderate Buy” and an average target price of $595.75.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock opened at $573.07 on Thursday. The firm has a 50-day moving average price of $504.04 and a 200-day moving average price of $453.30. The firm has a market capitalization of $216.40 billion, a PE ratio of 33.11, a price-to-earnings-growth ratio of 3.24 and a beta of 0.77. The company has a current ratio of 1.50, a quick ratio of 1.50 and a debt-to-equity ratio of 0.62. Thermo Fisher Scientific has a 12-month low of $385.46 and a 12-month high of $610.97.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, beating analysts’ consensus estimates of $5.50 by $0.29. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The company had revenue of $11.12 billion during the quarter, compared to analyst estimates of $10.90 billion. During the same quarter last year, the business posted $5.28 EPS. The firm’s revenue for the quarter was up 4.9% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. As a group, equities research analysts forecast that Thermo Fisher Scientific will post 23.28 EPS for the current year.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 400 shares of the business’s stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $500.50, for a total transaction of $200,200.00. Following the sale, the chief executive officer owned 113,762 shares of the company’s stock, valued at approximately $56,937,881. The trade was a 0.35% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CAO Joseph R. Holmes sold 385 shares of the business’s stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the sale, the chief accounting officer directly owned 2,319 shares in the company, valued at approximately $1,142,408.97. This represents a 14.24% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 29,666 shares of company stock worth $13,990,971. 0.33% of the stock is owned by insiders.

Institutional Trading of Thermo Fisher Scientific

Several large investors have recently made changes to their positions in the business. Norges Bank acquired a new position in shares of Thermo Fisher Scientific in the 2nd quarter valued at $2,264,615,000. Soundwatch Capital LLC acquired a new position in shares of Thermo Fisher Scientific in the 2nd quarter valued at $807,713,000. Flossbach Von Storch SE raised its position in Thermo Fisher Scientific by 93.0% during the second quarter. Flossbach Von Storch SE now owns 2,727,021 shares of the medical research company’s stock worth $1,105,698,000 after acquiring an additional 1,314,182 shares during the period. Nuveen LLC acquired a new position in Thermo Fisher Scientific during the first quarter worth $532,360,000. Finally, EdgePoint Investment Group Inc. raised its position in Thermo Fisher Scientific by 282.5% during the second quarter. EdgePoint Investment Group Inc. now owns 1,323,065 shares of the medical research company’s stock worth $536,450,000 after acquiring an additional 977,127 shares during the period. 89.23% of the stock is owned by hedge funds and other institutional investors.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.